Lanoracopan for treating PNH
Part of Blood & lymphatic clinical trials.
This study tests a new medicine called lanoracopan for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes red blood cells to break down too early. The medicine aims to control the disease and improve blood counts, potentially reducing anemia and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have PNH that is either newly diagnosed with active breakdown of red blood cells, or you have been on certain existing treatments (like eculizumab or iptacopan) without enough improvement, or you cannot tolerate those treatments.
- You have had or will have the recommended vaccines for meningitis and pneumonia, or you take antibiotics until the vaccines work.
- You agree to follow the study plan and give written permission to take part.
- You do not have a history of bone marrow or stem cell transplant, or removal of the spleen.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication, iptacopan, for children with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood condition. It aims to see how well the drug works in kids who have not tried anti-C5 therapy or who are switching from it.
This trial tests a new pill called MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where red blood cells are destroyed. If you have moderate anemia and high LDH (a marker of blood cell breakdown), this study may be an option.
This trial tests pegcetacoplan in children (ages 12–17) with paroxysmal nocturnal hemoglobinuria (PNH), a condition that can cause ongoing blood cell breakdown. The goal is to see if the medicine can improve anemia related to PNH.
This trial tests an experimental RNA drug (ALN-CFB) for people with PNH who still have low red blood cell counts despite taking a C5 inhibitor. The drug aims to block a protein (complement factor B) to improve anemia.
This trial tests a new drug called SLN12140 for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not received complement inhibitor therapy. It aims to see if the drug can help control PNH symptoms.
This study tests an investigational oral medication called TUL321 in healthy volunteers to see if it is safe and how the body handles it. It may help understand the drug's effects and is an early step in developing a new treatment.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria, PNH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.